ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01698736
Recruitment Status : Completed
First Posted : October 3, 2012
Last Update Posted : January 17, 2018
Fresenius Medical Care Deutschland GmbH
Information provided by (Responsible Party):
Farsad Eskandary, Medical University of Vienna